Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Upregulated MicroRNA-25 Mediates the Migration of Melanoma Cells by Targeting DKK3 through the WNT/β-Catenin Pathway.

Huo J, Zhang Y, Li R, Wang Y, Wu J, Zhang D.

Int J Mol Sci. 2016 Oct 27;17(11). pii: E1124.

2.

In the Wnt-er of life: Wnt signalling in melanoma and ageing.

Kaur A, Webster MR, Weeraratna AT.

Br J Cancer. 2016 Nov 22;115(11):1273-1279. doi: 10.1038/bjc.2016.332. Epub 2016 Oct 20.

3.

Wnt signaling in cancer.

Zhan T, Rindtorff N, Boutros M.

Oncogene. 2017 Mar;36(11):1461-1473. doi: 10.1038/onc.2016.304. Epub 2016 Sep 12. Review.

4.

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A.

Cancer Immunol Res. 2016 Oct;4(10):845-857. Epub 2016 Sep 2.

PMID:
27589875
5.

A PGC1α-mediated transcriptional axis suppresses melanoma metastasis.

Luo C, Lim JH, Lee Y, Granter SR, Thomas A, Vazquez F, Widlund HR, Puigserver P.

Nature. 2016 Sep 15;537(7620):422-426. doi: 10.1038/nature19347. Epub 2016 Aug 31.

6.

Wnt signalling is a bi-directional vulnerability of cancer cells.

Duffy DJ, Krstic A, Schwarzl T, Halasz M, Iljin K, Fey D, Haley B, Whilde J, Haapa-Paananen S, Fey V, Fischer M, Westermann F, Henrich KO, Bannert S, Higgins DG, Kolch W.

Oncotarget. 2016 Sep 13;7(37):60310-60331. doi: 10.18632/oncotarget.11203.

7.

Casein kinase 1α has a non-redundant and dominant role within the CK1 family in melanoma progression.

Sinnberg T, Wang J, Sauer B, Schittek B.

BMC Cancer. 2016 Aug 3;16:594. doi: 10.1186/s12885-016-2643-0.

8.

Modeling Melanoma In Vitro and In Vivo.

Beaumont KA, Mohana-Kumaran N, Haass NK.

Healthcare (Basel). 2013 Dec 23;2(1):27-46. doi: 10.3390/healthcare2010027. Review.

9.

β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation.

Sastre-Perona A, Riesco-Eizaguirre G, Zaballos MA, Santisteban P.

Oncotarget. 2016 Aug 2;7(31):49435-49449. doi: 10.18632/oncotarget.10356.

10.

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW.

Pigment Cell Melanoma Res. 2016 Sep;29(5):590-7. doi: 10.1111/pcmr.12498. Epub 2016 Aug 3.

11.

Oncogenic BRAF-Mediated Melanoma Cell Invasion.

Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W.

Cell Rep. 2016 May 31;15(9):2012-24. doi: 10.1016/j.celrep.2016.04.073. Epub 2016 May 19.

12.

Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.

Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, Smyth MJ.

Oncoimmunology. 2015 Dec 10;5(3):e1089381. eCollection 2016 Mar.

13.

Tumor-intrinsic oncogene pathways mediating immune avoidance.

Spranger S, Gajewski TF.

Oncoimmunology. 2015 Aug 31;5(3):e1086862. eCollection 2016 Mar. Review.

14.

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M.

Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012.

15.

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY.

Cell Rep. 2016 Apr 5;15(1):171-80. doi: 10.1016/j.celrep.2016.03.006. Epub 2016 Mar 24.

16.

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.

Spranger S.

Int Immunol. 2016 Aug;28(8):383-91. doi: 10.1093/intimm/dxw014. Epub 2016 Mar 17. Review.

PMID:
26989092
17.

DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.

Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M.

Cell Rep. 2016 Mar 8;14(9):2180-92. doi: 10.1016/j.celrep.2016.02.010. Epub 2016 Feb 25.

18.

Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Spranger S, Sivan A, Corrales L, Gajewski TF.

Adv Immunol. 2016;130:75-93. doi: 10.1016/bs.ai.2015.12.003. Epub 2016 Jan 22.

19.

Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations.

Venkatesan N, Kanwar J, Deepa PR, Khetan V, Crowley TM, Raguraman R, Sugneswari G, Rishi P, Natarajan V, Biswas J, Krishnakumar S.

PLoS One. 2016 Jan 26;11(1):e0146128. doi: 10.1371/journal.pone.0146128. eCollection 2016.

20.

Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus.

Pai P, Rachagani S, Dhawan P, Batra SK.

Carcinogenesis. 2016 Mar;37(3):223-32. doi: 10.1093/carcin/bgw005. Epub 2016 Jan 13. Review.

Supplemental Content

Support Center